|
|
|
|
Ticlopidine,an antiplatelet agent with a unique mechanism of action,is now available for clinical use in the United States and Canada.Recently two large randomized trials demonstrated that ticlopidine can reduce the risk of subsequent stroke i patients presenting with a transient ischemic attack or stroke.One study found that ticlopidine was more effective than aspirin for stroke prevention;however,it was less well tolerated than aspirin and was associated with severe but reversible neutropenia in almost 1%of patients.Conclusions:Ticlopidine is effective for both primary and secondary stroke prevention.It has a favorable risk/benefit ratio and is a particularly attractive option for patients who are unable to take aspirin. |
|